Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | ASH 2020: myeloma transplantation highlights

Jeffrey Matous • 11 Dec 2020
ASH 2020
Multiple Myeloma Bortezomib Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide
EMN02 FORTE IFM 2009

Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, highlights the exciting updates in transplantation data in multiple myeloma presented at ASH 2020. He focuses on the findings of the FORTE (NCT02203643), IFM 2009 (NCT03679351) and EMN02 (NCT01208766) trials, which all take different approaches to improve the overall quality of life, as well as response and survival rates in myeloma patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Jeffrey Matous

1:51
The use of BTK inhibitors in R/R and treatment-naïve patients with WM
Jeffrey Matous • 10 Dec 2023
2:58
MonumenTAL-2: talquetamab plus pomalidomide in R/R multiple myeloma
Jeffrey Matous • 10 Dec 2023
3:47
ALLO-715 and ALLO-647: novel CAR-T products in R/R myeloma
Jeffrey Matous • 11 Dec 2020
1:39
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Jeffrey Matous • 6 Dec 2014

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals